Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients

Cancer Research

Volumn 56, Issue 16, 1996, Pages 3689-3694

  Rivory, Laurent P ^a,c   Riou, Jean François ^b   Haaz, Marie Christine ^d   Sable, Serge ^b   Vuilhorgne, Marc ^b   Commerçon, Alain ^b   Pond, Susan M ^a   Robert, Jacques ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SANOFI   (France)

^c INSTITUT BERGONIÉ   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; ACETYLCHOLINESTERASE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBOXYLESTERASE; DNA TOPOISOMERASE; DRUG METABOLITE; IRINOTECAN; NEOSTIGMINE METHYL SULFATE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL TRIAL; DNA CLEAVAGE; DOSE RESPONSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INHIBITION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MASS SPECTROMETRY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID PHASE EXTRACTION;

EID: 0029760995     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sawada, S., Okajima, S , Aiyama, R., Nokata, K , Furuta, T., Yokokura, T., Sugino, E , Yamaguchi, K., and Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin Chem & Pharm. Bull. (Tokyo), 39 1446-1454, 1991.
2. Potmesil, M. Camptothecins: from bench research to hospital wards Cancer Res , 54 1431-1439, 1994.
3. Kawato, Y., Aonuma, M., Hirota, Y , Kuga, H , and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CFT-11, in the antitumor effect of CPT-11. Cancer Res , 57 4187-4191, 1991.
4. Rivory, L. P., and Robert, J. Identification and kinetics of a β-glucuronide of SN-38 in human plasma after administration of the camptothecin derivative irinotecan (CPT-11). Cancer Chemother. Pharmacol , 36: 176-179, 1995.
5. Rivory, L. P., and Robert, J Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan. CPT-11, and its metabolite SN-38 in plasma J. Chromatogr. 661 133-141, 1994.
6. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Form, M., Extra, J-M., Mahjoubi, M., Herait, P., Armand, J-P., Bugat, R., Clavel, M., and Marty, M. E. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during Phase I trials. Ann Oncol , 6: 141-151, 1995
7. Rowinsky, E K., Gruchow, L. B., Eltinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T-L., Rock, M K , and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
8. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J-P., Roché, H., Bugat, R., Gonçalvès, E., and Mathieu-Boué, A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine Cancer Chemother. Pharmacol., 36: 79-82, 1995
9. Madelaine, I., Prost, S., Naudin, A., Riou, G , Lavelle, F., and Riou, J. F. Sequential modifications of topoisomerase I activity in a camptothecin resistant cell line established by progressive adaptation Biochem. Pharmacol., 45: 339-348, 1993
10. Kjeldsen, E , Mollerup, S., Thomsen, B., Bonven, B. J , Bolund, L., and Westergaard, O. Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage. J. Mol. Biol , 202: 333-342, 1988.
11. Riou, J. F., Gabillot, M., Phillipe, M , Schrevel, J., and Riou, G. Purification and characterization of Plasmodium berghei DNA topoisomerase I and II: drug action, inhibition of decatenation and relaxation, stimulation of DNA cleavage. Biochemistry, 25: 1471-1479, 1986.
12. Berthou, F., Ratanasavanh, D., Riché, C., Picart, D , Voisin, T., and Guillouzo, A. Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver Xenobiotica, 19: 401-407, 1989
13. Rivory, L. P , Bowles, M. R., Robert, J., and Pond, S. M. The conversion of CPT-11 (irinotecan) to its active metabolite, SN-38, by human liver carboxylesterase. Biochem. Pharmacol , in press, 1996.
14. Kawato, Y., Seiguchi, M., Akahane, K , Tsunomi, Y., Hirota, Y., Kuga, H , Susuki, W , Hakusui, H., and Sato, K Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholinesterase receptors in rats. J. Pharm. Pharmacol., 45: 444-448, 1993
15. Ellman, G. L , Courtney, K. D., Andres, V , and Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol , 7: 88-95, 1961.
16. Rivory, L. P , Canal, P , Lokiec, F., Armand, J. P., Chatelut, E , Mathieu-Boué, A., and Robert, J. Inter-relationship of the pharmacokinetics of SN-38 and its β-glucuronide in patients treated with irinotecan (CPT-11). Proc. Am. Assoc Cancer Res., 36: 233, 1995
17. Matsumoto, H , Ohta, S., and Hirobe, M. Application of chemical cytochrome P-450 model systems to studies on drug metabolism IV. Mechanism of piperidine metabolism pathways via an iminium intermediate Drug Metab. Dispos., 19, 768-780, 1991.
18. Tsuji, T., Kaneda, N , Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio -Dyn , 14: 341-349, 1991.
19. Inoue, M., Morikawa, M , Tsuboi, M., Ito, Y., and Sugiura, M. Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolizing activity for ester-type drags. Jpn. J. Pharmacol. 30: 529-535, 1980.